These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16049884)

  • 1. [Current treatment of hepatitis C virus infection].
    Lörke J; Avci A; Erhardt A; Heintges T; Häussinger D
    Dtsch Med Wochenschr; 2005 Jul; 130(30):1773-7. PubMed ID: 16049884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence.
    Biliotti E; Zacharia S; Grieco S; Spaziante M; Giusto M; Merli M; Gallinaro V; Taliani G
    J Chemother; 2012 Dec; 24(6):369-72. PubMed ID: 23174103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
    Bizollon T; Ducerf C; Trépo C
    J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging strategies for pegylated interferon combination therapy.
    Schiff ER
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S17-21. PubMed ID: 17235281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
    Chen J; Shi J; Xie WF; Zeng X; Lin Y
    Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
    Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
    Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.